Ipsen, BAKX Therapeutics collaborate to broaden their oncology therapy portfolio

EUROPE – Ipsen, a French based company, has entered into collaboration with BAKX Therapeutics with an aim to focus on an oral small-molecule activator of BAX for the potential treatment of leukemia, lymphoma and solid tumors. Under the terms of the deal, Ipsen will collaborate with BAKX Therapeutics to research, develop, manufacture and commercialize BKX-001 in these oncology indications. BAX is a novel target in the apoptosis cell-signaling pathway apoptosis is the naturally occurring process of programmed cell death. Global Immuno- oncology clinical trials market Based on a report from…

Read More

Regeneron, AstraZeneca collaborate to venture into obesity drug market

WORLD – Regeneron and AstraZeneca enter into a partnership that will focus on researching, developing and commercializing small molecule medicines targeting GPR75 for the treatment of obesity. GPR75 has emerged as a potential target for the treatment of obesity and its related co-morbidities, following findings published by Regeneron a few weeks ago in Science. The new target was identified by sequencing almost 650,000 people and identifying individuals with rare protective mutations. According to the analysis, individuals with at least one inactive copy of the GPR75 gene had lower body mass…

Read More